UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
American journal of hematology, ISSN 0361-8609, 04/2014, Volume 89, Issue 4, pp. 410 - 416
Life Sciences & Biomedicine | Hematology | Science & Technology | Azacitidine - adverse effects | Sepsis - etiology | Compassionate Use Trials | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Remission Induction | Antimetabolites, Antineoplastic - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Azacitidine - therapeutic use | Cohort Studies | Cytogenetics | Chemotherapy | Analysis | Cancer | Leukemia | Medical prognosis | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antineoplastic Agents - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Aminoglycosides - adverse effects | Aminoglycosides - therapeutic use | Bone marrow | Chemotherapy | Mutation | Transplants & implants | Toxicity | Drug dosages | Index Medicus | Abridged Index Medicus | Thrombocytopenia | Intravenous administration | Motivation | Antibodies | Clinical trials | Platelets | Gemtuzumab ozogamicin | Survival | Antineoplastic Agents | Aminoglycosides | Leukemia, Myeloid, Acute | Life Sciences | Antibodies, Monoclonal, Humanized | Cancer
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 01/2020, Volume 21, Issue 1, p. 164
Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Recurrence | Ribonucleosides - therapeutic use | Apoptosis - drug effects | Leukemia, Myeloid, Acute - pathology | Aminoimidazole Carboxamide - therapeutic use | Humans | Middle Aged | Male | Clinical Trials as Topic | Aminoimidazole Carboxamide - pharmacology | Ribonucleosides - pharmacology | Aminoimidazole Carboxamide - analogs & derivatives | Treatment Failure | Cell Line, Tumor | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Cell Proliferation - drug effects | Myelodysplastic Syndromes - pathology | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Drug Resistance, Neoplasm - drug effects | Index Medicus | aml | apoptosis | phase i/ii clinical trial | acadesine | mds | azacitidine
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4533 - 4540
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Azacitidine - adverse effects | Humans | Middle Aged | Induction Chemotherapy | Male | Treatment Outcome | Combined Modality Therapy | Myelodysplastic Syndromes - etiology | Antimetabolites, Antineoplastic - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Female | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Myelodysplastic Syndromes - surgery | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Transplantation, Homologous - methods | Index Medicus | Myelodysplastic Syndromes | Hematopoietic Stem Cell Transplantation | Transplantation, Homologous | Life Sciences | Immunology | Azacitidine | Antimetabolites, Antineoplastic
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 383, Issue 9936, pp. 2239 - 2252
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | T-Lymphocytes - physiology | Diagnosis, Differential | Prognosis | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Mutation - genetics | Myelodysplastic Syndromes - etiology | Myelodysplastic Syndromes - diagnosis | Myelodysplastic Syndromes - therapy | Stem Cell Transplantation - methods | Epigenesis, Genetic - genetics | Hematopoiesis - physiology | Cytogenetic Analysis | Myelodysplastic syndromes | Transplants & implants | Gene expression | Clinical outcomes | Genotype & phenotype | Chemotherapy | Older people | Medical prognosis | Bone marrow | Epigenetics | Cytogenetics | Mutation | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 09/2008, Volume 113, Issue 6, pp. 1351 - 1361
prognosis in MDS | prognostic models | risk groups in MDS | chronic myelomonocytic leukemia | Prognosis in MDS | Prognostic models | Chronic myelomonocytic leukemia | Risk groups in MDS | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Models, Theoretical | Prognosis | Risk Assessment | Humans | Middle Aged | Myelodysplastic Syndromes - classification | Male | Survival Rate | Myelodysplastic Syndromes - diagnosis | Myelodysplastic Syndromes - therapy | Adolescent | Chromosome Aberrations | Aged, 80 and over | Adult | Female | Aged | Myelodysplastic Syndromes - genetics | Chromosomes, Human, Pair 7 - genetics | Blast Crisis | Models | Research | Health risk assessment | Myelodysplastic syndromes | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 5, pp. 516 - 523
Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Erythropoietin - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Hematopoietic Stem Cell Transplantation | Azacitidine - analogs & derivatives | Recombinant Proteins | Transplantation, Homologous | Thalidomide - analogs & derivatives | Antimetabolites, Antineoplastic - therapeutic use | DNA Methylation | Myelodysplastic Syndromes - mortality | Epoetin Alfa | Thalidomide - therapeutic use | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | 5-aza-2'-deoxycytidine | Index Medicus | Review
Journal Article
Leukemia, ISSN 0887-6924, 10/2020, Volume 34, Issue 10, pp. 2552 - 2560
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Prognosis | Mortality | Stem cells | Cytogenetics | Development and progression | Transplantation | Hematopoietic stem cells | Myelodysplastic syndromes | Stem cell transplantation | Risk | Myelodysplastic syndrome | Hemopoiesis | Index Medicus
Journal Article